Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses.
Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA.
- Published Article
Journal of Clinical Oncology
American Society of Clinical Oncology
- Publication Date
Feb 01, 2009
Sequential therapy with F-->C-->R yields improvement in quality of response, with many patients achieving a PCR-negative state.
Report this publication
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 07/07/2017 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/19075280